Cargando…

Insulin Therapy and Cancer

Detalles Bibliográficos
Autor principal:	Home, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Diabetes and Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920801/ https://www.ncbi.nlm.nih.gov/pubmed/23882052 http://dx.doi.org/10.2337/dcS13-2002

Ejemplares similares

Do GLP-1–Based Therapies Increase Cancer Risk?
por: Nauck, Michael A., et al.
Publicado: (2013)

Should A1C Targets Be Individualized for All People With Diabetes?: Arguments for and against
por: Teoh, Hwee, et al.
Publicado: (2011)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Epidemiology and Molecular Mechanisms Tying Obesity, Diabetes, and the Metabolic Syndrome With Cancer
por: Gallagher, Emily J., et al.
Publicado: (2013)

Recombinant Human Insulins – Clinical Efficacy and Safety in Diabetes Therapy
por: Landgraf, Wolfgang, et al.
Publicado: (2016)

Expectations about and experiences with insulin therapy contribute to diabetes treatment satisfaction in insulin-naïve patients with type 2 diabetes
por: Naegeli, A N, et al.
Publicado: (2010)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Insulin and cancer: a tangled web
por: Leitner, Brooks P., et al.
Publicado: (2022)

A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study
por: Ito, Hiroyuki, et al.
Publicado: (2018)

Cultural adaptation of a patient decision-aid for insulin therapy
por: Tan, Ngiap Chuan, et al.
Publicado: (2020)

Insulin Glulisine in Pregnancy – Experience from Clinical Trials and Post-marketing Surveillance
por: Doder, Zoran, et al.
Publicado: (2015)

Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes
por: Nallicheri, Armaan, et al.
Publicado: (2022)

Prolonged remission in latent autoimmune diabetes of adults (LADA): Is insulin resistance a major influence?
por: Rocha, José Vicente, et al.
Publicado: (2023)

‘Is Insulin Right for Me?’ Development of a theory-informed, web-based resource for reducing psychological barriers to insulin therapy in type 2 diabetes
por: Holloway, Edith E, et al.
Publicado: (2021)

A Comparison of Insulin Pen Devices and Disposable Plastic Syringes – Simplicity, Safety, Convenience and Cost Differences
por: Singh, Ripudaman, et al.
Publicado: (2018)

Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

Web-based intervention to reduce psychological barriers to insulin therapy among adults with non-insulin-treated type 2 diabetes: study protocol for a two-armed randomised controlled trial of ‘Is insulin right for me?’
por: Holmes-Truscott, Elizabeth, et al.
Publicado: (2022)

PSUN264 Insulin Edema: A rare side effect of Intensive Insulin Therapy
por: Abramowitz, Jessica, et al.
Publicado: (2022)

Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis
por: Freemantle, Nick, et al.
Publicado: (2016)

The Cost-effectiveness of a Flash Glucose Monitoring System for Management of Patients with Type 2 Diabetes Receiving Intensive Insulin Treatment in Sweden
por: Bilir, S Pinar, et al.
Publicado: (2018)

Cost-effectiveness Analysis of a Flash Glucose Monitoring System for Patients with Type 1 Diabetes Receiving Intensive Insulin Treatment in Sweden
por: Bilir, S Pinar, et al.
Publicado: (2018)

The association between insulin therapy and depression in patients with type 2 diabetes mellitus: a meta-analysis
por: Bai, Xiaosu, et al.
Publicado: (2018)

Cost Calculation for a Flash Glucose Monitoring System for Adults with Type 2 Diabetes Mellitus Using Intensive Insulin – a UK Perspective
por: Hellmund, Richard, et al.
Publicado: (2018)

Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140–2147
por: Home, Philip D.
Publicado: (2013)

The Insulin Treatment Satisfaction Questionnaire and Assessment of Satisfaction with a Latest-generation Insulin Pump
por: Bromba, Michael, et al.
Publicado: (2015)

Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol
por: Ziegler, Anette-Gabriele, et al.
Publicado: (2019)

Clustered Mendelian randomization analyses identify distinct and opposing pathways in the association between genetically influenced insulin-like growth factor-1 and type 2 diabetes mellitus
por: Wang, Wenyi, et al.
Publicado: (2022)

In Vivo Actions of Peroxisome Proliferator–Activated Receptors: Glycemic control, insulin sensitivity, and insulin secretion
por: Eldor, Roy, et al.
Publicado: (2013)

Use of insulin degludec/aspart after resolution of euglycemic diabetic ketoacidosis associated with dapagliflozin in a female patient with newly diagnosed maturity onset diabetes of the young type 3
por: Ayhan, Ihsan, et al.
Publicado: (2023)

What determines treatment satisfaction of patients with type 2 diabetes on insulin therapy? An observational study in eight European countries
por: Boels, Anne Meike, et al.
Publicado: (2017)

The Role of Insulin and Insulin-like Growth Factors in the Increased Risk of Cancer in Diabetes
por: LeRoith, Derek, et al.
Publicado: (2011)

LBODP063 The Benefits Of Using Cgm For Intravenous Insulin Therapy
por: Bublik, Evgeniya, et al.
Publicado: (2022)

Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease
por: Yarchoan, Mark, et al.
Publicado: (2014)

Insulin Action in Brain Regulates Systemic Metabolism and Brain Function
por: Kleinridders, André, et al.
Publicado: (2014)

Acylcarnitines: Reflecting or Inflicting Insulin Resistance?
por: Schooneman, Marieke G., et al.
Publicado: (2013)

Closing in on the Mechanisms of Pulsatile Insulin Secretion
por: Bertram, Richard, et al.
Publicado: (2018)

Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy (CLOuD study): a randomised parallel study protocol
por: Boughton, Charlotte, et al.
Publicado: (2020)

Cytochrome c in cancer therapy and prognosis
por: Pessoa, João
Publicado: (2022)

Insulin Therapy for Type 2 Diabetes
por: Swinnen, Sanne G., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_kbaohl2vj3j24omo84qootts56